FY2025 EPS Estimates for Insulet Boosted by Leerink Partnrs

Key Points

• Analysts at Leerink Partners have increased their FY2025 earnings estimate for Insulet Corporation from $4.61 to $4.62 per share, surpassing the current consensus estimate of $3.92.
• Insulet's stock has been rated as a "Moderate Buy" by 18 equities research analysts, with an average price target of $348.05.
• Insulet reported a significant quarterly earnings beat, posting $1.17 EPS versus an estimated $0.92, along with a year-over-year revenue increase of 32.9%.

Insulet Corporation (NASDAQ:PODD - Free Report) - Analysts at Leerink Partnrs raised their FY2025 earnings estimates for shares of Insulet in a research report issued to clients and investors on Tuesday, October 14th. Leerink Partnrs analyst M. Kratky now forecasts that the medical instruments supplier will post earnings of $4.62 per share for the year, up from their previous estimate of $4.61. The consensus estimate for Insulet's current full-year earnings is $3.92 per share. Leerink Partnrs also issued estimates for Insulet's FY2026 earnings at $6.03 EPS, FY2027 earnings at $7.72 EPS, FY2028 earnings at $9.60 EPS and FY2029 earnings at $11.55 EPS.

Several other brokerages also recently issued reports on PODD. Canaccord Genuity Group upped their price target on shares of Insulet from $353.00 to $399.00 and gave the stock a "buy" rating in a research report on Monday, September 29th. Morgan Stanley reissued an "overweight" rating on shares of Insulet in a report on Thursday, August 7th. Leerink Partners boosted their price objective on Insulet from $339.00 to $355.00 and gave the stock an "outperform" rating in a report on Tuesday. Barclays boosted their price objective on Insulet from $266.00 to $300.00 and gave the stock an "equal weight" rating in a report on Thursday, August 21st. Finally, Citigroup reissued a "buy" rating on shares of Insulet in a report on Tuesday, July 8th. Eighteen equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $348.05.

Insulet Stock Up 1.2%

Shares of NASDAQ PODD opened at $318.30 on Wednesday. The firm's 50-day simple moving average is $325.03 and its 200 day simple moving average is $301.15. The company has a market cap of $22.41 billion, a price-to-earnings ratio of 96.75, a price-to-earnings-growth ratio of 2.63 and a beta of 1.40. The company has a quick ratio of 1.81, a current ratio of 2.26 and a debt-to-equity ratio of 0.64. Insulet has a 12-month low of $226.50 and a 12-month high of $353.50.

Insulet (NASDAQ:PODD - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $1.17 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.92 by $0.25. The business had revenue of $649.10 million for the quarter, compared to the consensus estimate of $612.31 million. Insulet had a net margin of 10.01% and a return on equity of 23.78%. The firm's quarterly revenue was up 32.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.55 EPS. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS.

Insider Activity at Insulet

In related news, SVP Laetitia Cousin sold 797 shares of the firm's stock in a transaction on Monday, September 8th. The stock was sold at an average price of $348.81, for a total value of $278,001.57. Following the transaction, the senior vice president owned 3,890 shares in the company, valued at approximately $1,356,870.90. This trade represents a 17.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Prem Singh sold 687 shares of the firm's stock in a transaction on Monday, September 8th. The stock was sold at an average price of $347.49, for a total value of $238,725.63. Following the completion of the transaction, the senior vice president owned 3,456 shares in the company, valued at $1,200,925.44. The trade was a 16.58% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 0.39% of the company's stock.

Institutional Trading of Insulet

Large investors have recently bought and sold shares of the business. Farther Finance Advisors LLC lifted its stake in shares of Insulet by 85.1% in the first quarter. Farther Finance Advisors LLC now owns 896 shares of the medical instruments supplier's stock worth $236,000 after acquiring an additional 412 shares during the period. GAMMA Investing LLC lifted its stake in shares of Insulet by 4.3% in the first quarter. GAMMA Investing LLC now owns 2,529 shares of the medical instruments supplier's stock worth $664,000 after acquiring an additional 105 shares during the period. Wealth Enhancement Advisory Services LLC lifted its stake in shares of Insulet by 13.9% in the first quarter. Wealth Enhancement Advisory Services LLC now owns 3,028 shares of the medical instruments supplier's stock worth $795,000 after acquiring an additional 370 shares during the period. Exchange Traded Concepts LLC lifted its stake in shares of Insulet by 225.4% in the first quarter. Exchange Traded Concepts LLC now owns 1,552 shares of the medical instruments supplier's stock worth $408,000 after acquiring an additional 1,075 shares during the period. Finally, Janney Montgomery Scott LLC lifted its stake in shares of Insulet by 2.9% in the first quarter. Janney Montgomery Scott LLC now owns 5,405 shares of the medical instruments supplier's stock worth $1,419,000 after acquiring an additional 154 shares during the period.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.